(1S,2R,3S)- 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)- 4- methoxyphenyl)- 2,3- dihydro- 5- propoxy- 1H-Indene-2-carboxylic acid

an ET(A) and ET(B) endothelin receptor antagonist; structure in first source

Also Known As:

1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1S,2R,3S)-; 3-(2-(carboxymethoxy)-4-methoxyphenyl)-1-(3,4-(methylenedioxy)phenyl)-5-(prop-1-yloxy)indan-2-carboxylic acid; SB 209670; SB-209670

Networked: 27 relevant articles (3 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Miyauchi, Takashi: 2 articles (11/2014 - 01/2004)
2.	Islam, Md Majedul: 1 article (11/2014)
3.	Jesmin, Subrina: 1 article (11/2014)
4.	Kamiyama, Junko: 1 article (11/2014)
5.	Kawano, Satoru: 1 article (11/2014)
6.	Khatun, Tanzila: 1 article (11/2014)
7.	Mizutani, Taro: 1 article (11/2014)
8.	Mowa, Chishimba Nathan: 1 article (11/2014)
9.	Oki, Masami: 1 article (11/2014)
10.	Sakuramoto, Hideaki: 1 article (11/2014)

Related Diseases

1.	Neointima 05/01/1995 - "Since it was previously shown that the ETA/B antagonist SB 209670 was effective in this model, while the ETA selective antagonist BQ-123 is now found to be ineffective, the data implicate the ETB receptor subtype in the pathogenesis of neointima formation." 01/01/1995 - "Therefore, since chronic administration of pharmacologic doses of the ETA-selective antagonist BQ-123 does not prevent lesion formation in the RCCA model, whereas the ETA/B receptor antagonist SB 209670 is vasculoprotective, the data implicate a significant role for the ETB receptor subtype, either exclusively or in concert with ETA receptor activation, in the pathogenesis of neointima formation in the rat." 08/16/1994 - "SB 209670 produces a dose-dependent reduction in blood pressure in hypertensive rats, protects from ischemia-induced neuronal degeneration in a gerbil stroke model, and attenuates neointima formation following rat carotid artery balloon angioplasty. " 01/01/1995 - "Acute intra-arterial infusion (0.1 mg/kg/min) for 2 h at the time of angioplasty of either BQ-123 or SB 209670 did not attenuate the neointima lesion formation observed 2 weeks after angioplasty (neointima:media ratios of 137% and 116% of control, respectively). " 01/01/1995 - "Endothelin receptor subtypes in the pathogenesis of angioplasty-induced neointima formation in the rat: a comparison of selective ETA receptor antagonism and dual ETA/ETB receptor antagonism using BQ-123 and SB 209670."
2.	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 08/01/1995 - "For example, SB 209670, a rationally designed, potent, nonpeptide endothelin receptor antagonist, exerts therapeutic efficacy in reducing vasospasm following subarachnoid hemorrhage and neuroprotection following ischemic stroke. " 12/01/1994 - "(+/-)-SB 209670, a potent nonpeptide endothelin (ET) receptor antagonist, was used to investigate the potential role of ET in cerebral vasospasm associated with subarachnoid hemorrhage. "
3.	Ventricular Premature Complexes (Premature Ventricular Contraction) 10/01/1996 - "We observed (1) in hearts treated with ramiprilat (100 nmol/L) or captopril (5 mumol/L), a significant reduction of ET-1 secretion under all three experimental conditions and fewer ventricular extrasystoles during reperfusion; (2) increased ET-1 secretion and numerous tachyarrhythmic events in the presence of ACE inhibitor and a bradykinin B2 receptor antagonist, icatibant (100 nmol/L); (3) an almost-complete suppression of reperfusion arrhythmias when an ET receptor antagonist, ie, SB 209670 (5 mumol/L) or PD 142893 (200 nmol/L), was infused together with ACE inhibitor and icatibant; and (4) SB 209670 alone to be equally antiarrhythmic as ACE inhibitors. "
4.	Ischemic Stroke 08/01/1995 - "For example, SB 209670, a rationally designed, potent, nonpeptide endothelin receptor antagonist, exerts therapeutic efficacy in reducing vasospasm following subarachnoid hemorrhage and neuroprotection following ischemic stroke. "
5.	Ischemia 10/01/1995 - "In contrast, when infused at 30 micrograms/kg.min for 3 hr on the day after ischemia, (+/-)-SB 209670 markedly increased survival rate (75%) in rats with severe ARF by significantly increasing tubular reabsorption of Na+, followed by a slow and gradual increase in GFR and reversal of the increase in plasma K+ concentration. " 10/01/1995 - "Data from acute renal clearance studies in rats with moderate ARF showed that when infused 24 hr after ischemia, (+/-)-SB 209670 acutely reversed the impairment in sodium reabsorption without increasing GFR or renal blood flow.(ABSTRACT TRUNCATED AT 250 WORDS)" 01/01/1999 - "Three nephrectomized groups that did not undergo ischemia but that received infusions of saline (N = 6), PD 156707 (N = 6), and SB 209670 (N = 6), respectively, were also studied. " 01/01/1999 - "Twenty-four hours after renal ischemia, one of two ETR antagonists, PD 156707 (N = 7) or SB 209670 (N = 8), was administered. " 10/01/1995 - "Infusion of (+/-)-SB 209670 at 10, 30 and 100 micrograms/kg.min for 30 min before, during and 60 min after renal ischemia had a moderate effect on renal function. "

Related Drugs and Biologics

1.	Endothelin Receptor Antagonists
2.	cyclo(Trp-Asp-Pro-Val-Leu)
3.	Bradykinin B2 Receptor
4.	Captopril (Capoten)
5.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
6.	PD 142893
7.	icatibant
8.	ramiprilat
9.	Endothelins (Endothelin)
10.	SB 234551

Related Therapies and Procedures

1.	Intravenous Administration
2.	Intra-Arterial Infusions